ES2596720B1 - Compositions for topical use - Google Patents

Abstract

Compositions for topical use. # The present invention relates to compositions suitable for topical administration of cosmetic or pharmacological active ingredients. The present invention also refers to the use of said preparations in the treatment and / or non-therapeutic cosmetic care of the skin and / or hair; as well as its use in medicine, in particular, for the treatment and / or prevention of pathological conditions of the skin and / or hair.

Description

Compositions for topical use

Field of the Invention

The present invention is framed in the field of compositions for topically administering cosmetic or pharmacological active ingredients. The present invention also refers to the use of said compositions in the non-therapeutic cosmetic treatment and / or the care of the skin and / or hair; as well as its use in medicine, in particular, for the treatment and / or prevention of pathological conditions of the skin and / or hair.

Background of the invention

Topical administration of cosmetic or therapeutic agents is a challenge in the field of cosmetic formulations! Pharmaceuticals

The skin is a barrier of the body that acts as a protective shield against the environment.

Mammalian skin consists of two main layers: the epidermis and the dermis. The epidermis is formed by the stratum corneum, granular stratum, spiny stratum and basal stratum, the stratum corneum constituting the surface of the skin and the basal stratum constituting the deepest part of the epidermis. The dermis is under the epidermis and consists mainly of collagen.

The main function of the skin is the regulation of the entry of substances into the body. The stratum corneum provides the main barrier function in the permeability of the skin; It measures between 15 and 20 ... 1m thick and consists of 15 to 20 layers of compressed cells, densely clustered, and metabolically inactive, followed by several histologically distinguishable layers formed by clusters, wall to wall, of cells. On the other hand, the membranes of epidermal cells are so tightly bound that there is hardly any intercellular space through which to diffuse polar non-electrolytic molecules

or ions The proteins and lipids of the stratum corneum form a complex interlocking structure, as if they were bricks and lipid mortar. The main lipids found in the stratum corneum include cholesterol and fatty acids. Ceramides, in particular, ceramide 2 and ceramide 5, play a very important role in the general organization of the lipid matrix of the stratum corneum, and in the skin's barrier function. Ceramides are strongly grouped within the lipid layers due to the strength of hydrogen bonds between the groups with opposite amide terminations. This fact indicates that there is a transverse organization in addition to the orthorhombic lateral organization of the ceramide molecule chain. The hydrogen bond provides the resistance, integrity and barrier properties to the lipid layers of the stratum corneum. This layer is very selective with the typology of molecules transportable through the skin; thus, only molecules with specific physical-chemical properties can cross the skin significantly.

The assumptions regarding the absorption of substances in the skin are referred to diffusion through the lipid area of the stratum corneum. More recently, it has become known that hair follicles are involved in the percutaneous absorption process since they represent a weak point in the shield that forms the skin.

Regarding this fact, topical administration through the hair follicle of active ingredients to the different layers of the skin, including the epidermis and dermis (US) has been described.

2005/02386061.

The nanoparticles have been extensively studied as topical drug delivery systems, in particular, as a reservoir on the surface of the skin from which in a controlled manner the release over time of a drug can be achieved, however in such nanoparticle systems do not penetrate beyond the surface layers of the skin barrier (Campbell et aL, J Control Release, 2012, 162, 201

207].

In other administration systems, nanoparticles have been described to penetrate the follicular orifice. However, these nanoparticles remain in the follicle, but their penetration into the viable skin tissue has not been detected (Lademann et al., Skin Pharmaco / App / Skin Physio /., 1999, 12, 247-561.

There is a need to find topical administration systems for cosmetic and pharmacological active ingredients that are capable of penetrating the skin efficiently and that allow the transfolicular absorption of nanoparticles.

Summary of the Invention

The first aspect of the present invention is related to a composition that understands: a) an oil with a value 00 from 15 to 18, a t5p value from 2 to 5 and an OH value from 2 to 5; b) a surfactant selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or stearyl alcohol with 10 to 22 units of ethylene oxide, laurates of sorbitan, 0leal05 sorbitan, polysorbates and mixtures thereof; e) a nanoparticle selected from the group consisting of nanoparticles of hydroxyapatite, tri-calcium phosphate nanoparticles, poly-lactic acid-co nanoparticles glycolic, hyaluronic acid nanoparticles and mixtures thereof; d) a cosmetically or pharmacologically active ingredient with Bo, Bp and ÓH such that

.) 4 (00 19.5) '+ (op 10.1)' + (OH 13.0) ''; 9;

e) optionally, an absorption aid through the skin; and f) optionally water;

J112

where BD, Bp YÓH are Hansen's solubility parameters expressed in · cm-3/2.

In a second aspect, the present invention refers to the use of a composition according to the first aspect, in which the active ingredient is a pharmaceutical active ingredient, to prepare a medicament.

In a third aspect, the present invention refers to the use of a composition according to the first aspect, in which the active ingredient is an active pharmacological ingredient, in the preparation of a medicament for the treatment and / or prevention of a pathology of the skin and / or hair selected from a group consisting of microbial infections, fungal infections, and pathological hair loss.

In a fourth aspect, the present invention refers to the use of a composition according to the first aspect, in which the active ingredient is a cosmetic active ingredient, in the cosmetic treatment and / or non-therapeutic care, of the skin and / or hair

Description of the invention

Hansen parameter determination

Hansen's solubility parameters were developed by Charles Hansen as One way to predict whether one material will dissolve in another. There are three Hansen parameters: -oo, which corresponds to the energy of the dispersion force between the molecules, -op, which corresponds to the energy of the intermolecular dipole force between the molecules, and -ÓH, which corresponds to the energy of the hydrogen bonds between the molecules.

These three parameters can be treated as coordinates to represent a point in a three-dimensional space, also known as the Hansen space. The closer two molecules are in this three-dimensional space, the more likely they are to dissolve with each other.

The Hansen parameters of a compound can be determined following the binary solvent gradient method published by Machui et al. [Solar Energy Materials Solar Cel / s, 2012, 100, 13.8-146]. This method analyzes the solubility of any compound in a series of solvents with known Hansen parameters (as described for example in Hansen SolubiJity Parameters: A Users' Handbook. With a database updated at http://hansen-solubility.com /Contents/HSPiPDataSet.xls). The Hansen parameters of said compound are located in the center of a sphere in the Hansen space where the radius R indicates the maximum difference in the tolerable affinity for complete dissolution, as explained below. Good solvents remain inside the sphere and bad solvents remain outside the sphere.

In a first step the solubility of the compound in a reduced number of pure solvents is determined, in order to identify at least one good solvent and one bad solvent for the compound. The solvents used in this first stage are, for example, toluene, propylene carbonate, 2-propanol, acetonitrile, hexane and dimethylsulfoxide (DMSO), isopropyl myristate, dicaprilyl ether, water, tetrahydrofuran, glycerol, diethylene glycol, can also be used. dimethyl formamide and 1,4-dioxane. The determination is made by stirring the compound under study (approximately 70 mg) with approximately 5 ml of each of the solvents mentioned above for 30 minutes at 800 rpm. Next, the sample is examined visually and the solvent is classified as a "good solvent" if a clear solution or a suspension that does not form sediments is obtained after standing for 1 hour. Otherwise the solvent is classified as a "bad solvent." Next, binary mixtures of solvents are used, which comprise a good solvent and a bad solvent in a volume ratio of 3: 1, 2: 3

and 1: 3, or if more values are necessary to improve the accuracy of the binary solvent mixture method, the mixtures may comprise a good solvent and a bad solvent in a volume ratio of 17:86, 29:71, 43 : 57, 57:43, 71: 29 and 86:14, although other volume ratios can also be used.

The Hansen parameters of a binary solvent mixture correspond to the sum of the volume contributions of each solvent. For example, the Hansen parameters of a mixture containing 29% by volume of a good solvent A, represented by the Hansen parameters ÓOA, OPA and ÓHA, and 71% by volume of a bad solvent B represented

10 by parameters Hansen 1508, OPP AND ÓHB. It would be calculated as follows: i5ome ~ cla = 0.29-i50A + 0.71-50B i5pme ~ cla = 0.29-i5PA + 0.71-5PB i5Hme ~ cla = 0.29-i5HA + 0.71 -i5HB

15 Table 1 shows the Hansen parameter values of some pure solvents_

Table 1_ Hansen parameters of solubility of some pure solvents_

Solvent

Order op Oh

Toluene

18 1.4 2

Propylene Carbonate

twenty 18 4.1

2-Propanol

15.8 601 16.4

Acetonitrile

15.3 18 6.1

Hexane

14.9 OR OR

Isopropyl Myristate

16.2 2.4 3.7

Ether Dicaprilil

16.1 2.2 2

Water

15.5 16 42.3

Tetrahydrofuran

16.8 5.7 8

Glycerol

17.4 11, 3 27.2

Diethylene glycol

16.6 12 19

Dimethyl formamide

17.4 13.7 11, 3

1,4-Dioxane

17.5 1.8 9

Next, the solubility of the compound under study in said binary mixtures of solvents is evaluated, assigning a score of 1 to 6 to each sample, as detailed (the assessment is carried out visually observing the result of the mixture of the

composed with the solvent (s) in a glass test tube or other suitable container of a transparent material and with the help of a millimeter paper bottom, with the following parameters):

1 = completely dissolved (no aggregates) and no turbidity (clear solution);

2 = completely dissolved (no aggregates) and turbidity (you can see the graph paper

background);

3 = completely dissolved (without aggregates) and strong turbidity (you cannot see the role of

background graphic);

4 = Not completely dissolved (small aggregates) and strong turbidity (cannot be seen

the background graphic paper);

5 = Not completely dissolved (small aggregates) and turbidity (you can see the paper

background graphic);

6 = Do not touch (large aggregates) and without turbidity (clear solution).

The solution refers to the loss of integrity of the compound and to be visibly less massive. Turbidity refers to the degree of transparency, the limits being a clear solution and the ability to see through an unclear solution.

In the case of particles, such as nanoparticles representing component c) of the composition of the present invention, "solubility" is determined as the sedimentation rate or lack thereof. The sedimentation rate is the time for the nanoparticles studied to settle in the solvent (in particular in the binary mixtures of solvents defined above) and quantified by the relative sedimentation time (RST) using the following formula:

RST = t, (pp -p,) / ~ where ts is the settling time (expressed in seconds), pp is the density of particles (expressed in g / mi), Ps is the density of the solvent (in particular of the binary solvent mixture; expressed in g / mi) and '1 is the viscosity of the solvent (in particular of the binary solvent mixture; expressed in mpa · s). The assignment of the score from 1 to 6 from the RST values is carried out by assigning the score 6 to the shortest times of all the solvents studied for the same particle (in particular of all the binary mixtures of solvents studied), while the longest and most stable dispersions obtained lower values when applying the following equation:

Score = n - ((n-1) 'RSTlMaxRST)

where n is the value of the maximum study score (for example 6), RST is the relative settling time and MaxRST is the maximum value of the relative settling time obtained in the study (that is, for the same particle in all the solvents, in particular in the binary mixtures of solvents tested). The score value obtained is rounded to the unit.

The solvents of the binary mixtures are represented in the Hansen space according to their Hansen parameters, and the Hansen parameters of the particular compound are then calculated by adjusting a solubility sphere in which all good solvent mixtures are within it (i.e., those with scores of 1-3) and all bad solvent mixtures are found outside of it (i.e., those with scores of 4-6). An algorithm adjusts a sphere in 3D Hansen space (50, 5p and 5t-t) minimizing the number of so-called erroneous solvents, which includes a) good solvents that are outside the sphere and b) bad solvents inside the sphere. It is established that if there are different spheres without erroneous solvents, the sphere with the smallest radius is selected. If there are different spheres with the same number of erroneous solvents, the sphere is selected with the lowest error distance (distance from a bad solvent inside the sphere or distance from a good solvent outside the sphere). This adjustment is made by evaluating the data using the following adjustment quality formula:

DATAFIT = (A, A, ... A ,,) 1 / n, where n is the number of solvents, and A, = e- (error distance), where the error distance is the distance between the wrong solvent and the edge of the sphere.

Ai will be equal 1.0 when there is a good solvent inside the sphere, and when there is a bad solvent outside the sphere.

The coordinates of the center of the sphere correspond, accordingly, to the Hansen 50, 5p Y5t-t parameters of the molecule under study.

Compositions of the invention

Component a) of the composition, according to the first aspect of the present invention is an oil having a value 50 of 15 to 18, a 5p value of 2 to 5 and an ot-t value of

2 to 5. Preferably, the oil has an OD value of 15.5 to 16.5. Preferably, the oil has an op value of 2 to 3. Preferably, the oil has an OH value of 2 to 4. More preferably, the oil has an 15.5 to 16.5, an op value of 2 to 3 and an OH value of

2 to 4 5

The term "oil" is used in the present invention to designate any liquid organic substance at 20 ° C, which has a water solubility of less than 0.05 gIl, preferably less than 0.01 gIl, more preferably less than 0.001 gIl, even more preferably less than 0.0001 gIl. The oil includes petroleum derivatives, or oils of

10 animal, plant or synthetic origin, whose Hansen parameter values are as defined above.

Non-limiting examples of oils having a Bo value of 15 to 18, a Bp value of 2 to 5 and a BH value of 2 to 6 are; Isopropyl myristate, dicaprilyl ether, squalane, oleyl erucate,

15 Oleyl oleate, isopropyl palmitate, acai oil, sweet almond oil, soy glycerides, avocado oil and shea butter, whose Hansen parameters are listed in Table 2.

Table 2. Hansen solubility parameters of some oils.

Oil Isopropyl myristate Dicaprilyl ether Squalane Oily erucato Olello oleate Isopropyl palmitate Acai oil Sweet almond oil Soy glycerides Avocado oil Shea butter

ORD 16.2 16.1 15.8 16.0 16.0 16.2 16 16 16 16 16 op 2.4 2.2 2.1 2.2 2.3 2.3 3 3 3 3 3 OH 3.7 2.0 2.2 2.3 2.4 3.8 3 3 2 2 3

In a preferred embodiment, the oil is selected from the group consisting of isopropyl myristate, dicaprilyl ether, squalane, avocado oil and mixtures thereof.

Preferably, the oil (component a »is present in an amount of 60% to 90% by weight with respect to the total weight of the composition, more preferably from 65% to 90% by weight with respect to the total weight of the composition.

Component b) of the composition according to the first aspect of the present invention is a surfactant selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or stearyl alcohol with 10 to 22 units of ethylene oxide, sorbitan laurals, oleals of sorbitan, polysorbates and mixtures thereof.

Oleyl alcohol polyethylene glycol ethers are known as Oleth followed by the number of ethylene oxide units, for example, Oleth-10 is the oleyl alcohol polyethylene glycol ether comprising 10 ethylene oxide units. Non-limiting examples of oleic alcohol polyethylene glycol ethers with 10 to 22 ethylene oxide units are Oleth-10, Oleth-11, Oleth-12, Oleth-15, Oleth-16 and Oleth-20.

Stearyl alcohol polyethylene glycol ethers are known as Steareth followed by the number of ethylene oxide units, for example Steareth-10 is stearyl alcohol polyethylene glycol ether comprising 10 units of ethylene oxide. Non-limiting examples of polyethylene glycol ethers of stearyl alcohol with 10 to 22 units of ethylene oxide are Steareth-10, Steareth-11, Steareth-12, Steareth-13, Steareth-14, Steareth-15, Steareth-16, Steareth- 20 and Steareth-21.

Sorbitan laurates means sorbitan monolaurate, sorbitan dilaurates, sorbitan trilaurate and mixtures thereof.

Sorbitan oleates means sorbitan monooleate, sorbitan dioleates, sorbitan trioleate, and mixtures thereof.

Polysorbates are sorbitan esters with fatty acids such as lauric acid, palmitic acid, stearic acid and oleic acid. The number that follows the polysorbate part is related to the type of fatty acid associated with the polyoxyethylene sorbitan part of the molecule. Monolaurate is indicated at 20, monopalmitate is indicated at 40, monostearate at 60 and monooleate at 80. Non-limiting examples of polysorbates are polysorbate-20, polysorbate-21, polysorbate-40, polysorbate-60, polysorbate -61, polysorbate-65, polysorbate-80, polysorbate-81 and polysorbate-85.

In a preferred embodiment, the surfactant is selected from the group consisting of Oleth10, Oleth-11, Oleth-12, Oleth-15, Oleth-16, Oleth-20, sorbitan monooleate, sorbitan trioleate, polysorbate-20, polysorbate- 21, polysorbate-40, polysorbate-60, polysorbate-61, polysorbate-65, polysorbate-80, polysorbate-81, polysorbate-85 and mixtures thereof; more preferably the surfactant is selected from the group consisting of Oleth-10, sorbitan monooleate, polysorbate 80 and mixtures thereof.

Preferably, the surfactant (component b)) is present in an amount of 0.25% to 2% by weight with respect to the total weight of the composition.

Component e) of the composition according to the first aspect of the present invention is a nanoparticle selected from the group consisting of hydroxyapatite nanoparticles, tri-calcium phosphate nanoparticles, poly-Ictic-coglycolic acid nanoparticles (PLGA), nanoparticles of hyaluronic acid and mixtures thereof.

In the context of the present invention, "nanoparticle" means a particle, preferably a spherical particle, with a diameter of 1 nm to 1000 nm, preferably 1 nm to 500 nm, even more preferably 1 nm to 400 nm, even more preferably from 10 nm to 350 nm, even more preferably from 50 nm to 300 nm, and more preferably from 100 nm to 250 nm.

Preferably, the nanoparticles (component c)) are present in an amount of 0.5% to 2% by weight with respect to the total weight of the composition.

Preferably, when the nanoparticle is a PLGA nanoparticle, the surfactant (component b)) is selected from the group consisting of Oleth-10, Oleth-11, Oleth-12, Oleth-15, Oleth-16 and Oleth-20; preferably from the group consisting of Oleth-10, Oleth-12 and mixture thereof; more preferably, the surfactant is Oleth-10.

Preferably, when the nanoparticle is a hydroxyapatite nanoparticle, the surfactant (component b)) is selected from the group consisting of sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and mixtures thereof.

Preferably, when the nanoparticle is a tricalcium phosphate nanoparticle, the surfactant (component b)) is selected from the group consisting of polysorbate-20,

polysorbate-21, polysorbate-40, polysorbate-60, polysorbate-61, polysorbate-65, polysorbate-BO, polysorbate-81, polysorbate-85 and mixture thereof; preferably, the surfactant is polysorbate-80.

5 Preferably, when the nanoparticle is a hyaluronic acid nanoparticle, the surfactant (component b "is selected from the group consisting of polysorbate-20, polysorbate-21, polysorbate-40, polysorbate-60, polysorbate-61, polysorbate-65, polysorbate-BO, polysorbate-81, polysorbate-85 and mixture thereof; preferably, the surfactant is polysorbate-80.

The component d) of the composition according to the first aspect of the present invention is a cosmetically or pharmacologically active ingredient with OD, OP and OH such that) 4 (OD 19.5) '+ (op 10.1) '+ (OH 13.0)' S 9

15 where OD, OP and OH are the Hansen solubility parameters of the cosmetically or pharmacologically active ingredient expressed in J112 · cm · 312. These Hansen parameters can be determined as explained above.

A cosmetically active ingredient is a compound or mixture of compounds that exerts

20 a beneficial effect on the skin and / or hair, such as the improvement or maintenance of the cosmetic qualities of the skin and / or hair, for example the level of hydration, elasticity, firmness, brightness, tone and texture, among others.

A pharmacologically active ingredient is a compound or mixture of compounds that

25 prevents and / or treats a disease or disorder of the skin and / or hair, such as microbial infections, fungal infections, and / or pathological loss of hair, among others.

In a preferred embodiment, the cosmetically active ingredient is selected from the group

30 consisting of antioxidants, moisturizers, skin conditioning agents, antistatic agents, softening agents, soothing agents, emollient agents, astringent agents, anti-seborrheic agents, anti-dandruff agents, tonics, bleaching agents, cleansing agents, keratolytic agents, lipid agents, agents with tensor effect, anti-wrinkle agents, repairing agents, regenerating agents, firming agents,

35 energizing agents, bulking agents, anti-dark agents, anti-bag agents, pore-minimizing agents, protective agents and mixtures thereof;

or the pharmacologically active ingredient is selected from the group consisting of antimicrobial agents, anti-inflammatory agents, fungicides, agents that prevent hair loss.

When mixtures of cosmetically or pharmacologically active ingredients are used, the Hansen parameters of the mixture correspond to the sum of the contributions by weight of each of the compounds.

An antioxidant is a compound that inhibits reactions caused by oxygen, thus preventing oxidation reactions. These compounds also prevent the enrancimienlo of the compositions. Non-limiting examples of antioxidants having suitable oo,? Ip and Ó¡. values are CameJ / ia sinensis leaf extract, trans-resveratrol, alpha-lipoic acid, nordihydroguaiartic acid, caffeine, Aloe vera, ascorbyl palmitate, alpha -arbutin, arbutin, Echinacea pupurea extract, niacinamide and yastaxanthin.

A moisturizer is a compound that increases the water content of the skin and helps keep it soft and smooth. Non-limiting examples of moisturizers having suitable 15 °, OP YOH values are Echinacea pupurea extract, niacinamide and pyroglutamic acid.

A skin conditioning agent is a compound that keeps the skin in good condition. Non-limiting examples of skin conditioning agents having suitable? Io,? Ip and Ó¡.¡ values are Echinacea pupurea extract, CameJ / ia sinensis leaf extract, salicylic acid, biotin, Helichrysum arenarium flower extract, extract of Chamomilla recutita flower, Ginkgo biloba leaf extract, Aloe vera, caprililo glycol, Ranunculus ficaria extract, Centella asiatica extract, Aesculus hippocastanum seed extract, ethyl nicotinate, glycyretinic acid, alpha-arbutin, arbutin, extract of Enanta chlorantha bark, astaxanthin, flower extract of Spilanthes acmella and benzyl nicotinate.

An antistatic agent is a compound that reduces static electricity, neutralizing the electrical charge on a surface. Non-limiting examples of antistatic agents having suitable 6 0, OP and OH values are niacin, acrylate copolymer and benzyl nicotinate.

A softening agent is a compound that decreases the roughness of the skin or its irregularities, thus achieving a smooth skin surface. Non-limiting examples of softening agents having suitable Oo, i5p and i5H values are niacin, Spirulina maxima extract, niacinamide and Centella asia / jea extract.

A soothing agent is a compound that helps relieve discomfort in the skin or scalp. Non-limiting examples of soothing agents that have i5o values. Suitable OP and OH are methyl nicotinate, Centella asiatica extract and Echinacea pupurea extract.

An emollient agent is a compound that softens the skin. Non-limiting examples of emollient agents having suitable o, op and OH values are CameJ / ia sinensis leaf extract, Panax ginseng root extract, glyceryl stearate, and caprililglycol.

An astringent agent is a compound that contracts the skin. A non-limiting example of an astringent agent having suitable 0o, op and OH values is the leaf extract.

Camellia sinensis.

An antiseborrhoeic agent is a compound that helps control sebum production. Non-limiting examples of antiseborrhoeic agents having suitable 0o, op and OH values are biotin and Enantia eh / orantha bark extract.

An anti-dandruff agent is a compound that helps control dandruff. A non-limiting example of an anti-dandruff agent having suitable 0o, op and OH values is salicylic acid.

A tonic is a compound that produces a feeling of well-being in the skin and hair. Non-limiting examples of tonics having suitable 0o, op and OH values are Echinacea pupurea extract, Camellia sinensis leaf extract, Panax ginseng root extract, methyl nicotinate and Centella asiatiea extract.

A bleaching agent is a compound that lightens skin tone or corrects imperfections in skin pigmentation by decreasing the concentration of melanin. Non-limiting examples of bleaching agents having suitable 0o, op and OH values are glabridin, alpha-arbutin yarbutin.

A cleaning agent is a compound that helps keep the surface of the body (skin and / or hair) clean. Non-limiting examples of cleaning agents having suitable 150 • oP and OH values are Centella asiatica and alpha-lipoic acid.

A keratolytic agent is a compound that helps remove dead cells from the corneal layer. A non-limiting example of a keratolytic agent that has 15o values, suitable YÓH is salicylic acid.

A lipid agent is a compound that replenishes the lipids of the hair or upper layers of the skin. A non-limiting example of a lipid agent having suitable 50, OP and Oh values is ceramide C (6).

A tensor effect agent is a compound that tightens the skin. A non-limiting example of an agent with tensor effect having suitable i5o, i5p and i5H values is the acrylate copolymer.

An anti-wrinkle agent is a compound that can reduce fine lines on the skin. Non-limiting examples of anti-wrinkle agents having suitable i5o, 6p Yi5H values are ascorbyl palmitate and niacinamide.

A repairing agent is a compound that helps the body restore alterations produced in the skin such as scars. Non-limiting examples of repair agents having suitable i5o, i5p and i5H values are Centella asiatica extract and Echinacea purpurea extract.

A regenerating agent is a compound that helps the skin in its self-regeneration through mechanisms such as cell stimulation. A non-limiting example of a regenerating agent having suitable i5o, i5p and i5H values is Centella asiatica extract.

A firming agent is a compound that provides firmness to the skin. Non-limiting examples of firming agents having suitable i5o, i5p and 6H values are biotin and niacinamide.

An energizing agent is a compound that brings combined luminosity and astringency to the skin. Non-limiting examples of energizing agents that have i5o values.

Suitable Ó and ÓH are trans-resveratrol, Panax ginseng root extract, and Camellia sinensis leaf extract.

An agent that provides volume is a compound that stimulates skin adipocytes. A non-limiting example of an agent that provides volume having adequate 15o, oP and ÓH values is Centella asiatic8 extract.

An anti-dark agent is a compound that reduces pigmented areas under the eyes. Non-limiting examples of anti-dark agents that have suitable o, i p, and O 10 values are caffeine, Camellia sinensis leaf extract and Gingko biloba leaf extract.

An anti-bag agent is a compound that reduces swelling, usually in the area around the eye. Non-limiting examples of antibolous agents having suitable Bo, Bp and BH values are; Caffeine, Aesculus hippocasstanum seed extract and extract of

15 Chamomilla flower recutita.

A pore minimizing agent is a compound that helps clean pores and reduce their appearance. A non-limiting example of a pore minimizing agent that has adequate Bo, Bp and BH values is Rannuculus ficaria extract.

20 A protective agent is a compound that protects the skin against external agents. Non-limiting examples of protective agents having suitable Bo, Bp and BH values are trans-resveratrol, Centella asiatica extract and niacinamide.

25 An antimicrobial agent is a compound that helps control the growth of microorganisms in the skin. Non-limiting examples of antimicrobial agents having suitable Bo, Bp and BH values are Camellia sinensis leaf extract, ferulic acid, resorcinol hexyl, Enantia chlorantha bark extract and Sphilanthes acmella flower extract.

30 A fungicide is a compound that helps control the growth of fungus on the skin. A non-limiting example of a fungicide that has suitable oo, Bp and BH values is pyraclostrobin.

An anti-inflammatory agent is a compound that reduces inflammation. A non-limiting example of an anti-inflammatory agent that has adequate! 3o, oP and ÓH values is glabridin.

5 An agent that prevents hair loss is a compound that stimulates hair growth and / or prevents its loss. A non-limiting example of an agent that prevents hair loss that has adequate o, o, and? IH values is finasleride.

Therefore, in a particular embodiment, the present invention refers to a

Composition as defined herein, wherein the cosmetically or pharmacologically active ingredient is selected from the group consisting of Echinacea pupurea extract, niacin, CameJlia sinensis leaf extract, Spirulina maxima extract, salicylic acid, ferulic acid , biotin, Heliehrysum arenarium flower extract, acrylate copolymer, trans-resveratrol, Chamomilla reeutita flower extract,

15 niacinamide, alpha-lipoic acid, resorcinol hexyl, nordihydroguaiartic acid, Panax ginseng root extract, Ginkgo biloba leaf extract, pyraclostrobin, caffeine, pyroglutamic acid, ceramide C (6), glyceryl stearate, Aloe vera, palmitate ascorbyl, caprylic glycol, Rannuculus ficaria extract, methyl nicotinate, Centella asiatiea extract, Aesculus hippoeastanum seed extract, ethyl nicotinate, acid

20 glycyretin, alpha-arbutin, arbutin, bark extract of Enantia ehlorantha, astaxanthin, benzyl nicotinate, flower extract of Spilanthes aemeJla, finasteride, glabridin and mixtures thereof. Table 3 provides the OD, OP and OH values of some cosmetically or pharmacologically active ingredients.

25 Table 3. Hansen parameters of solubility of some cosmetically or pharmacologically active ingredients.

Assets

~ D ~ p ~ H

Echinacea pupurea Extract

19.7 10.4 13.5

Niacin

19.9 9 11, 4

CameJlia sinensis leaf extract

19.5 7.9 12.9

Spirulina maxima extract

19 10 fifteen

Salicylic acid

19.7 7.9 15.1

Ferulic acid

19.3 8.4 15.8

Biotin

18.7 12.9 12.2

Helichrysum flower extract

20.8 11, 6 16

Assets 00 arenarium Acrylate copolymer 17.8 Trans-resveratrol 20.6 Chamomilla flut extract reeutita 20 Niacinamide 19.8 Lipaic acid 18 resorcinol hexylo 18.2 Nordihydroguaaric acid 18.5 Panax ginseng root extract 18, 7 Ginkgo biloba leaf extract 16.9 Pyraclostrobin 20.1 Caffeine 19.5 Pyroglutamic acid 19.6 Ceramide C (6) 16.7 Glyceryl stearate 16.5 Aloe vera 17.6 Ascorbyl palmitate 16.7 Caprilylglycol 16 , 8 Ranunculus ficaria Extract 20 Methyl Nicotinalo 18.7 Centella asiatica Extract 17.8 Aesculus Seed Extract 20 hippocastanum Ethyl Nicotinate 18.3 Glycyretinic Acid 18.3 Alpha-Arbutin 18.4 Arbutin 18.4 Enanta Bark Extract 19.6 eh / orantha Astaxanthin 18.4 Benzyl Nicotinate 19.4 Spilanthes acmella Flour Extract 17.5 Finasteride 19

O, 7.5 7.5 11.6 15.4 7.1 5.4 5.2 5.4 11, 5 11, 4 10.1 15.2 8.4 8 14.1 6.8 5, 8 10 9 5.2 12 8.3 5.6 12.2 12.2 3.3 5.6 7.9 7.3 11 OH 12.7 15.9 17.1 13.1 9.5 11, 6 15 10.2 14.9 7.4 13 16 10.3 11, 8 16.4 11, 8 13.9 20 6.2 9.1 20 5.4 6.6 20.6 20.6 8 6.2 4.5 6 15

I Assets

In a particular embodiment, the ingredient cosmetically or pharmacologically has values of i5o. i5p YÓH such that

..) 4 (OD -19.5) 2+ (op 10.1) 2 + (OH 13.0) 2 "6,

where ÓD, op YÓH are the Hansen solubility parameters expressed in J1I2 · cm "3I2.

In a preferred embodiment, the active ingredient in the composition according to the present invention is a cosmetically active ingredient.

In another preferred embodiment, the active ingredient in the composition according to the present invention is a pharmacologically active ingredient.

Preferably, the cosmetic or pharmacologically active ingredient (component d)) is present in an amount of 2% to 15% by weight with respect to the total weight of the composition.

The compositions of the present invention may optionally comprise an absorption aid through the skin (component e.) Preferably, said absorption aid through the skin is present in the compositions of the invention.

An absorption aid through the skin is a compound that facilitates the passage of molecules through the corneal layer of the skin. Non-limiting examples of absorption aids through the skin are dimethyl isosorbide, transcutol (i.e. 2- (2-ethoxyethoxy) ethanol), propylene glycol, oleic acid, ethanol, dimethyl sulfoxide, dodecyl-N, N-dimethylaminoacetate, ethyl acetate , sodium dodecyl sulfate, d-limonene, 1,3-diphenylurea, Nmethyl-2-pyrrolidone, beta-cyclodextrin and Azone® (ie, N-dodecylcaprolactam). Preferably, the absorption aid through the skin is selected from the group consisting of dimethyl isosorbide, transcutol (ie 2- (2-ethoxyethoxy) ethanol) and mixtures thereof.

Preferably, the absorption aid through the skin (component e 'is present in an amount of 0.2% to 0.8% by weight with respect to the total weight of the composition.

The compositions of the present invention may optionally comprise water (component f ". Preferably, water is present in the compositions of the invention.

Preferably, water (component f "is present in an amount of 0.01% to 10% by weight with respect to the total weight of the composition.

In a particular embodiment, the composition of the present invention comprises: a) an oil selected from the group consisting of isopropyl myristate, ether of dicaprilil, escualano avocado oil and mixtures thereof; b) a surfactant selected from the group consisting of Oleth-10, sorbitan monooleate, sorbitan trioleate, polysorbate-80 and mixtures thereof; c) a nanoparticle selected from the group consisting of nanoparticles of hydroxyapatite, tricalcium phosphate nanoparticles, poly-Ictic acid-co nanoparticles glycolic, hyaluronic acid nanoparticles and mixtures thereof; d) a cosmetically or pharmacologically active ingredient with i5o, i5p Yi5H such that

.J4 (OD -19.5) '+ (op -10.1)' + (OH -13.0) '"6;

e) optionally, an absorption aid through the skin selected from the group consisting of dimethyl isosorbide, transcutol (ie 2- (2-ethoxyethoxy) ethanol) and mixtures of the themselves; Y

f) optionally water; where i5o, i5p Yi5H are the Hansen solubility parameters expressed in J1I2 · cm-312.

In another particular embodiment, the composition of the present invention comprises: a) 65% to 90% by weight with respect to the total weight of the composition of an oil selected from the group consisting of isopropyl myristate, dicaprilyl ether, squalane avocado oil and mixtures thereof; b) from 0.25% to 2% by weight with respect to the total weight of the composition of a surfactant selected from the group consisting of Oleth-10, sorbitan monooleate, trioleate sorbitan, polysorbate-80 and mixtures thereof;

e) from 0.5% to 2% by weight with respect to the total weight of the composition of a nanoparticle selected from the group consisting of hydroxyapatite nanoparticles, tricalcium phosphate nanoparticles, poly-Ictic-co-glycolic acid nanoparticles, hyaluronic acid nanoparticles and mixtures thereof; d) from 2% to 15% by weight with respect to the total weight of the composition of an ingredient cosmetically or pharmacologically active with ÓD, op Y ÓH such that

.J4 (oo -19.5) '+ (Op -10.1) 2 + (OH -13.0)': 5 9;

e) from 0.2% to 0.8% by weight with respect to the total weight of the composition of an adjuvant of the absorption in the skin selected from the group consisting of dimethyl isosorbide, transculol (ie 2- (2-ethoxyethoxy) ethanol) and mixtures thereof; Y f) from 0.01% to 10% by weight with respect to the total weight of the water composition; where i5o, i5p Yi5H are the Hansen solubility parameters expressed in J1I2 · cm · 3I2.

In another particular embodiment, the composition of the present invention comprises: a) 65% to 90% by weight with respect to the total weight of the composition of an oil selected from the group consisting of isopropyl myristate, dicaprilyl ether, squalane avocado oil and mixtures thereof; b) from 0.25% to 2% by weight with respect to the total weight of the composition of a surfactant selected from the group consisting of Oleth-10, sorbitan monooleate, trioleate sorbitan, polysorbate-80 and mixtures thereof; c) from 0.5% to 2% by weight with respect to the total weight of the composition of a nanoparticle selected from the group consisting of hydroxyapatila nanoparticles, tricalcium phosphate nanoparticles, poly-Ictic-co-glycolic acid nanoparticles, hyaluronic acid nanoparticles and mixtures thereof; d) from 2% to 15% by weight with respect to the total weight of the composition of an ingredient cosmetically or pharmacologically active with i5o, i5p Yi5H such that

.J4 (Oo 19.5) 2 + (Op 10.1) 2 + (OH 13.0) ': 5 6;

e) from 0.2% to 0.8% by weight with respect to the total weight of the composition of an adjuvant of the absorption in the skin selected from the group consisting of dimethyl isosorbide, transcutol (ie 2- (2-ethoxyethoxy) ethanol), and mixtures thereof; Y f) from 0.01% to 10% by weight with respect to the total weight of the water composition; where oo. Op and OH are the Hansen solubility parameters expressed in J 2cm3I2.

Preferably, the cosmetically or pharmacologically active ingredient in said specific compositions is selected from a group consisting of Echinacea extract.

pupurea, niacin, Camellia sinensis leaf extract, Spirulina maxima extract, salicylic acid, ferulic acid, biotin, Helichrysum arenarium flower extract, acrylate copolymer, trans-resveratrol, Chamomilla recutita flower extract, niacinamide, alfalipaic acid , resorcinol hexyl, nordihydroguaiartic acid, Panax ginseng root extract, Ginkgo biloba leaf extract, pyraclostrobin, caffeine, pyroglutamic acid, ceramide C (6), glyceryl stearate, Aloe vera, ascorbyl palmitate, caprilunculus, Rancum extract ficaria, methyl nicotinate, Centella Asiatica extract, Aesculus hippocastanum seed extract, ethyl nicotinate, glycyrrhizinic acid, alpha-arbutin, arbutin, Enanta chlorantha bark extract, astaxanthin, benzyl nicotinate, Spilanthes acmella flower extract , finasteride, glabridin and mixtures thereof.

The preparations of the present invention may also comprise additional ingredients. Such additional ingredients have 50, 5p YOH such that

) 4 (8D 19.5) 2 + (8p 10.1) 2 + (8 "13.0) 2 ,; 9 where 50. 5p Y5H are the Hansen solubility parameters expressed in JlI2 · cm · 3I2.

Non-limiting examples of such additional ingredients are emulsion stabilizing agents, emulsifiers, humectants, gelling agents, viscosity controlling agents, perfumes and preservatives.

An emulsion stabilizing agent is a compound that helps in the emulsification process and improves the stability of the emulsion and the shelf life of the preparations. Non-limiting examples of emulsion stabilizing agents having suitable 50, 5p and 5H values are carbomer, crosslinked polyacrylate-6 polymer and hydroxypropyl methyl cellulose.

An emulsifier is a compound that promotes the formation of intimate mixtures of non-miscible liquids by altering the interfacial tension. Non-limiting examples of emulsifiers having suitable o, o, and OH values are glyceryl stearate, polysorbate-20, octadecenedioic acid and PEG-60 almond glycerides.

A humectant is a compound that contains and retains moisture. Non-limiting examples of humectants having suitable 50, 5p and OH values are Camellia sinensis leaf extract, pyroglutamic acid, ceramide C (6) and Aloe vera.

A gelling agent is a compound that gives gel consistency to the composition. A non-limiting example of a gelling agent having suitable OD, OP and OH values is the carbomer.

A viscosity control agent is a compound that increases or reduces the viscosity of the composition. Non-limiting examples of viscosity control agents having suitable? ID,? Ip and OH values are carbomer, crosslinked polyacrylate-6 polymer, hydroxypropyl methyl cellulose and disodium EDTA.

A perfume is a compound used to perfume the compositions Non-limiting examples of perfumes that have OD values,? I and Y? JI-! Suitable are Citrus aurantium flower extract, phenylpropanol and ethyl nicotinate.

A preservative is a compound that stops or minimizes the deterioration caused by the presence of different types of microorganisms. Non-limiting examples of preservatives having suitable oi, oi Y5H values are methylpropanediol, caprylic glycol and phenylpropanol.

The preparations of the present invention may also comprise cyclopentasiloxane and / or cyclohexasiloxane. Preferably in an amount of 5% to 15% by weight with respect to to the total weight of the composition.

Other ingredients used in cosmetic preparations! pharmacological and known in the technique may also be present, preferably in an amount of less than 15% by weight with respect to the total weight of the composition.

In a preferred embodiment, the composition of the present invention comprises: a) from 65% to 90% by weight with respect to the total weight of the composition, of an oil that it has an Óo value of 16 to 118, an op value of 2 to 5, and an OH value of 2 to 5; b) from 0.25% to 2% by weight with respect to the total weight of the composition of a surfactant selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or alcohol stearyl having 10 to 22 units of ethylene oxide, sorbitan laurates, oleates of sorbitan, polysorbates and mixtures thereof; c) from 0.5% to 2% by weight with respect to the total weight of the composition, of a nanoparticle selected from the group consisting of hydroxyapatite nanoparticles, tricalcium phosphate nanoparticles, poly-Ictic-co-glycolic acid nanoparticles, hyaluronic acid nanoparticles and mixtures thereof;

d) from 2% to 15% by weight with respect to the tolal weight of the composition of a cosmetically or pharmacologically active ingredient with Ó, op Y ÓH such that

..j4 (lio -19.5) '+ (lip -10.1)' + (lin -13.0) '~ 9; e) from 0.2% to 0.8% by weight with respect to the total weight of the composition of an absorption aid through the skin; and f) from 0.01% to 10% by weight with respect to the tolal weight of the water composition; where OD, OP YÓH are Hansen solubility parameters expressed in J1I2 · cm "3a.

The compositions of the present invention have been designed for the topical administration of cosmetically or pharmacologically active ingredients. Therefore, the compositions of the present invention are topically shaped compositions.

In a preferred embodiment, the composition of the present invention is provided in the form of a cream, an emulsion, a lotion, an ointment, a gel, a foam, a paste, a balm, a milk, a serum or a solution.

Uses of the compositions of the invention

The term "treatment", as used in the context of this invention, when not accompanied by the qualifications "cosmetic, non-therapeutic", refers to the administration of a composition according to the invention to relieve or eliminate a disease or disorder or reduce or eliminate one or more symptoms associated with this disease or disorder.

The term "treatment", when accompanied by the qualifications "cosmetic, non-therapeutic", refers to the application of the composition of the invention on the skin and / or hair, in particular, with the aim of improving the cosmetic qualities of the skin and / or hair, such as, and not limited to these, its level of hydration, elasticity, firmness, wrinkles, shine, tone, or texture, among others.

The term "care" refers to the maintenance of the qualities of the skin and / or hair. These qualities are subject to improvement and maintenance through a cosmetic treatment and / or care of the skin and / or hair, both in healthy subjects and in those with diseases and / or disorders of the skin and / or hair.

The term "prevention", as used in this invention, refers to the ability of a composition of the invention to prevent, delay, or prevent the onset or development of a disease or disorder before its appearance.

The preparations of the present invention may comprise as a pharmacologically active ingredient, the active ingredient defined as component d).

Therefore, in a second aspect, the present invention refers to the use of a composition as defined above, in which the active ingredient is a pharmacologically active ingredient, to prepare a medicament.

The invention also refers to a composition according to the first aspect, in which the active ingredient is a pharmacologically active ingredient, for use in medicine.

In a third aspect, the present invention refers to the use of a composition according to the first aspect, in which the active ingredient is a pharmacologically active ingredient, in the manufacture of a medicament for the treatment and / or prevention of a pathological condition of the skin and / or hair, selected from the group consisting of microbial infections (such as acne), fungal infections (such as seborrheic dermatitis) and pathological hair loss.

The invention also refers to a composition according to the first aspect, in which the active ingredient is a pharmacologically active ingredient, for use in the treatment and / or prevention of a pathological condition of the skin and / or hair selected from the group that It consists of microbial infections, fungal infections and pathological hair loss.

The invention also refers to a method for the treatment and / or prevention of a pathological condition of the skin and / or hair selected from the group consisting of microbial infections, fungal infections and pathological hair loss, which comprises administration to a patient who needs said treatment and / or prevention of a therapeutically effective amount of a composition according to the first aspect in which the active ingredient is a pharmacologically active ingredient.

In a fourth aspect, the present invention refers to the use of a composition according to the first aspect, in which the active ingredient is a cosmetic active ingredient, in non-therapeutic cosmetic treatment and / or skin care and / or hair, preferably, in which the non-therapeutic cosmetic treatment and / or care of the skin and / or hair is selected from the group consisting of the treatment and / or prevention of aging and / or photoaging and the treatment and / or prevention of wrinkles

In the context of the present invention, the term "aging" refers to changes experienced by the skin with age (chrono-aging) or through exposure to the sun (photo-aging), or to extreme weather conditions of cold or wind , to chemical contaminants or pollutants, and includes all external changes visible and / or noticeable through touch, as non-limiting examples, the development of discontinuities in the skin such as wrinkles, fine lines, expression lines, stretch marks, wrinkles , irregularities or roughness, increased pore size, loss of hydration, loss of elasticity, loss of firmness, loss of softness, loss of ability to recover from deformations, loss of resilience, sagging skin such as sunken cheeks , the appearance of bags under the eyes, or the appearance of a double chin, among others, changes in skin color, such as marks, redness, bags or the appearance of hyperpigmented areas such as age spots

or freckles among others, anomalous differentiation, hyperkeratinization, elastosis, keratosis, hair loss, orange peel, loss of the collagen structure and other histological changes of the corneal layer, the dermis, epidermis, the vascular system (for example the appearance of spider veins or telangiectasias) or tissues near the skin, among others. The term "photoaging" groups the set of processes caused by prolonged exposure of the skin to ultraviolet radiation that results in premature aging of the skin and has the same physical characteristics as aging, as non-limiting examples, sagging , sinking, changes in color

or irregularities in pigmentation and abnormal and / or excessive keratinization. The sum of several environmental factors such as exposure to tobacco smoke, exposure to pollution and climatic conditions such as cold and / or wind also contribute to skin aging.

The compositions of the invention can be applied to the area of the skin and / or hair to be treated one or more times a day, such as 1 or 2, or 1, 2, or 3, or 1, 2, 3 or 4 times a day, preferably 1 or 2 times a day. Examples of preferable skin areas for treatment are the face, including the forehead, chin, nose, cheeks and the area around the eyes, such as the eyelids, the area under the eyes, the area between the eyes , the area around the eyes at the opposite end of the area between the eyes (usually where crow's feet appear), the neck and the neckline.

Preparation of the compositions

The compositions of the present invention can be prepared by any suitable method known in the field of topical pharmacological formulations, where the following are involved, by way of non-limiting example; premix, heat, cool, homogenize, mix, retrovaporate, filter, centrifuge, apply vacuum pressure, dry.

In a particular embodiment the preparation method comprises heating the fatty phase, or one or more of the oils, which have a Bo value of 15 to 18, a Bp value of 2 to 5 and a BH value of 2 to 5, that is , component a) of the composition of the present invention, in a fuser (reactor) up to 70 ° C with constant stirring with blades until complete homogenization. If the composition comprises optional water (component f) of the composition of the present invention), then said optional water is added to the reactor at room temperature and heated to 60 ° C with constant stirring with blades until complete homogenization.

One or more of the surfactants selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or stearyl alcohol having 10 to 22 units of ethylene oxide, sorbitan laurates, sorbitan oleates, polysorbates, i.e. , component b) of the composition of the present invention, with one or more of the nanoparticles selected from the group consisting of hydroxyapatite nanoparticles, tricalcium phosphate nanoparticles, poly-Ictic-co-glycolic acid nanoparticles, hyaluronic acid nanoparticles , that is, component c) of the composition of the present invention, optionally the absorption aid through the skin, that is, optional component d) of the composition of the present invention, and one or more of the cosmetically or pharmacologically active ingredients with 00, Bp and BH such that

J4 (OD 19.5) '+ (op 10.1)' + (OH 13.0) ': 5 9,

that is, component d) of the composition of the present invention.

Then the previously prepared fat phase (component a) and optionally water is cooled to 40 ° C and the premix of the components b) -d) and optionally e) is added to said fatty phase with constant stirring with blades until complete homogenization .

Examples Example 1

Composition for a day lotion:

Ingredient Squalane Avocado oil Polysorbate-BO Nanoparticles of Tricalcium Phosphate Echinacea pupurea extract Trans-resveratrol Ascorbyl palmitate Caffeine Citrus aurantium 2- flower extract (2 -eloxiethoxy) ethan 01) Water Cyclopentasiloxane Methylpropanyl glycol, caprol-olipol ) Crosslinked polyacrylate-6 polymer

% by weight 40 25 0.5 1 3 2 2 1 0.3 0.4 7.3 13.5 2 2

Example 2

Composition for a night cream:

Ingredient Squalane Sorbitan monooleate Hydroxyapatite nanoparticles Chamomilla flower extract recutita Centella asiatica extract Echinacea pupurea extract Alpha-arbutin Citrus aurantium flower extract 2- (2-ethoxyethoxy jetan 01 j

% by weight 79.5 1 2 3 2 2 2 0.4 0.8

Ingredient Water Methylpropanediol, caprylic glycol, phenylpropanol (preservative) Cross-linked polyacrylate-6 polymer

% by weight 3.3 2 2

Example 3 Composition for a serum:

Ingredient Squalane Avocado oil Polysorbate-80 Triccalcium Phosphate Nanoparticles Spilanthes acmella Aloe vera flower extract Spirulina maxima extract Panax ginseng root extract Niacinamide Ascorbyl palmitate Citrus aurantium flower extract 2- (2-eeloxyeto) Water Cyclopentasiloxane Methylpropanediol, caprilyl glycol, phenylpropanol (preservative) Cross-linked polyacrylate-6 polymer

% by weight 55 15 0.5 1 3 2 2 0.5 0.2 2 0.3 0.4 6.02 8.08 2 2

Claims (14)

1. A composition comprising: a) an oil having a value of 150 from 15 to 18, an value of 2 to 5 and an value of 2 to 5; 5 b) a surfactant selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or stearyl alcohol having from 10 to 22 units of ethylene oxide, sorbitan lauralos, sorbitan 0leat05, polysorbates and mixtures thereof; e) a nanoparticle selected from a group consisting of nanoparticles of hydroxyapatite, tricalcium phosphate nanoparticles, polylactic-co-glycolic acid nanoparticles, hyaluronic acid nanoparticles and mixtures thereof d) a cosmetically or pharmacologically active ingredient with? iD, Op and? JHtal that ../4(OD 19.5) 2 + (Op 10.1) 2 + (OH 13.0) 2: 5 9; e) optionally, an absorption aid through the skin; and 15 f) optionally water; J 112 312 where? iD,? ip YÓH are Hansen's solubility parameters expressed in · cm-. 2. A composition according to claim 1, wherein the oil is selected from the group consisting of isopropyl myristate, dicaprilyl ether, squalane avocado oil and 20 mixtures thereof. 3. A composition according to any of the preceding claims, wherein the surfactant is selected from the group consisting of Oleth-10, Oleth-11, Oleth-12, Oleth-15, Oleth-16, Oleth-20, sorbitan monooleate , trioleate, polysorbate-20, polysorbate-21, 25 polysorbate-40, polysorbate-60, polysorbate-61, polysorbate-65, polysorbate-80, polysorbate-81, polysorbate-85 and mixtures thereof. 4. A composition according to any of the preceding claims, wherein the nanoparticles have a size between 100 nm and 250 nm.

5.

A composition according to any of the preceding claims, wherein the absorption aid through the skin is present and is selected from the group consisting of dimethyl isosorbide, transcutol and mixtures thereof.

6.

A composition according to any one of the preceding claims, wherein the composition comprises: a) from 65% to 90% by weight with respect to the total weight of the composition of an oil having an O value of 16 to 18, an opal value of 2 to 5, and an OH value from 2 to 5;

b) from 0.25% to 2% by weight with respect to the total weight of the composition of a surfactant selected from the group consisting of polyethylene glycol ethers of oleyl alcohol or stearyl alcohol having 10 to 22 units of ethylene oxide, sorbitan laurates, 0leal05 sorbitan, polysorbates and mixtures thereof; e) from 0.5% to 2% by weight with respect to the total weight of the composition of a nanoparticle selected from the group consisting of hydroxyapatite nanoparticles, tricalcium phosphate nanoparticles, polylactic-co-glycolic acid nanoparticles, acid nanoparticles hyaluronic and mixtures thereof; d) from 2% to 15% by weight with respect to the total weight of the composition of a cosmetically or pharmacologically active ingredient with o, or p YÓH such that , / 4 (00 -19.5) '+ (op-10.1)' + (OH-13.0) '"9; e) from 0.2% to 0.8% by weight with respect to the total weight of the composition of an absorption aid through the skin; and f) from 0.01% to 1.0% by weight with respect to the total weight of the water composition; where? iD,? ip and? iH are the Hansen solubility parameters expressed in J 2cm3I2.

7.

A composition according to any of the preceding claims, which is provided in the form of a cream, an emulsion, a lotion, an ointment, a gel, a foam, a paste, a balm, a milk, a serum or a solution.

8.

A composition according to any of the preceding claims, wherein the cosmetically active ingredient is selected from the group consisting of antioxidants, moisturizers, skin conditioning agents, antistatic agents, softening agents, soothing agents, emollient agents, astringent agents, antiseborrhoeic agents , anti-dandruff agents, tonics, bleaching agents, cleaning agents, keratolytic agents, lipid agents, agents with tensile effect, anti-wrinkle agents, repairing agents, regenerating agents, firming agents, energizing agents, bulking agents, anti-dark agents, anti-bagging agents, agents pore minimizers, protective agents and mixtures thereof; or in which pharmacologically active ingredient is selected from the group consisting of agents

antimicrobials, anti-inflammatory agents, fungicides and agents that stimulate hair growth and / or prevent hair loss.

9.

A composition according to any of the preceding claims, wherein the active ingredient is a pharmacologically active ingredient.

10.

A composition according to any of the preceding claims, wherein the active ingredient is a cosmetically active ingredient.

eleven.

Use of a composition according to claim 9 to prepare a medicament.

12.

Use of a composition according to claim 9 in the manufacture of a medicament for the treatment and / or prevention of a pathological condition of the skin and / or hair selected from the group consisting of microbial infections, fungal infections, and pathological loss of hair.

13.

Use of a composition according to claim 10 for non-therapeutic cosmetic treatment and / or skin and / or hair care.

14.

Use according to claim 13, wherein the non-therapeutic cosmetic treatment and / or skin and / or hair care is selected from the group consisting of the treatment and / or prevention of aging and / or photoaging, treatment and / or Wrinkle prevention.